MedTrace Logo

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2020-04-21

Study results available
· View outcomes & findings →

Summary

An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine

Conditions

  • Migraine Disorder

Interventions

BIOLOGICAL

ALD403 (Eptinezumab)

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-04-30
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985398 on ClinicalTrials.gov